Potentially contributing to chemotherapy resistance, constitutive activation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway has been observed in CML (Dinner and Platanias, 2016). Here, AKT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.